iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Cipla to invest Euro 3 million Ethris

19 Jun 2024 , 11:26 AM

On Tuesday, June 18, pharmaceutical company Cipla announced that its wholly-owned UK subsidiary Cipla (EU) Limited will invest an extra 3 million euros in Ethris GmbH.

Ethris GmbH is an international leader in delivering ribonucleic acid (RNA) medicines directly to the respiratory system by inhalation.

Cipla stated in an exchange statement that this extra investment, made through a convertible loan, will accelerate the company’s engagement in the mRNA space.

Cipla previously inked binding agreements to invest 15 million euros in Ethris GmbH.

This additional investment demonstrates Cipla’s belief in Ethris’ proprietary mRNA technology and its promise for patients in emerging regions. Cipla and Ethris are forming a long-term strategic alliance to accelerate the development of novel mRNA-based treatments, according to the business.

During the Covid-19 pandemic, mRNA vaccines became increasingly important as the first regulatory authorization for SARS-CoV-2 were granted. mRNA-based medications have tremendous potential in a variety of applications, including infectious disease vaccines, therapeutic cancer vaccines, and protein replacement therapies.

Umang Vohra, Cipla’s Managing Director and Global Chief Executive Officer, stated, that at Cipla, we strive to increase our focus and investment in innovative modalities and bring new age therapies to emerging countries, including India. The additional investment in Ethris will assist bring cutting-edge healthcare solutions, such as mRNA-based medicines, to the Global South. As we lead Cipla forward, we will continue to seek to create an inventive future and brands that reinforce our attitude of ‘caring for life’.

At around 11.22 AM, Cipla was trading 0.75% lower at ₹1,563 per piece, against the previous close of ₹1,574.80 on NSE. The counter touched an intraday high and low of ₹1,582, and ₹1,557.15, respectively.

For feedback and suggestions, write to us at editorial@iifl.com

For opening a demat account click on: https://www.indiainfoline.com/

For doing stock trading & investments, go to: https://ttweb.indiainfoline.com/trade/Login.aspx

For loans, go to: https://www.iifl.com/

Related Tags

  • Cipla
  • Cipla Investment
  • Cipla news
  • Cipla Update
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.